Shire submits SPD465 for adult ADHD
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Shire's attention deficit/hyperactivity disorder agent SPD465 has an estimated May 21, 2007 user fee date following the firm's July 21 submission. The amphetamine compound is designed to provide sustained release of medication for 16 hours. SPD465 has the same active ingredient as the firm's Adderall XR (mixed amphetamine salts), which provides treatment for 12 hours...
You may also be interested in...
Shire submits Connexyn for ADHD
Shire submitted an NDA Aug. 24 for its attention deficit/hyperactivity disorder compound SPD503 (guanfacine) with the proposed trade name Connexyn. If approved, the drug would be the second non-stimulant product in its category. The company submitted another ADHD drug in July - SPD465 - designed to provide sustained release of medication for 16 hours. SPD465 has a May 21, 2007 standard review user fee date for treatment of adult ADHD; the agent has the same active ingredient as Shire's established Adderall brand (1Pharmaceutical Approvals Monthly August 2006, In Brief)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.